ISDS Case Map
medicines
The United States has throughout history been the principal demandeur of maximalist intellectual property, backed by a powerful pharmaceutical lobby.
The 10-year span is more than what had existed before but the biopharma industry has long argued for the same 12-year exclusivity that exists for biologics within the US market.
While some states in East and Southeast Asia favor the 16-nation RCEP trade deal, many civil society groups say it lacks transparency and public participation.
A leaked draft of the negotiating text has revealed some proposed harmful intellectual property provisions that could undermine access to price-lowering, generic medicines, and thus, life-saving treatment to millions of people.
Dr Othoman Mellouk is a Moroccan treatment advocate who has been working on intellectual property and access to medicines for more than a decade.
Trade Minister Steven Ciobo has promised to take a hard line with Europe on the question of cheap medicines and his counterpart Cecilia Malmström foresees “difficult” negotiations over Australian producers using European names such as "parmesan".
Government should reject Trump’s threat to affordable medicines through TPP and other trade deals.
Ukrainian lawmakers are poised to approve sweeping patent reform legislation, driven in large part by a push by patients’ groups for better access to affordable medicines and healthcare.
Extended patent protections under Canada’s free trade deal with the European Union could cost the federal government some $270 million a year, according to a new report by the Parliamentary Budget Officer.
A wide-ranging list of international nongovernmental organisations issued a letter to European Trade Commissioner Cecilia Malmström opposing a proposal to establish a “watch list” of countries deemed failing to protect European intellectual property.
